These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 19648168

  • 1. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
    Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG.
    Haematologica; 2009 Dec; 94(12):1669-75. PubMed ID: 19648168
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
    Berger U, Hehlmann R.
    Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
    [No Abstract] [Full Text] [Related]

  • 4. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F, SPIRIT Investigators, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).
    N Engl J Med; 2010 Dec 23; 363(26):2511-21. PubMed ID: 21175313
    [Abstract] [Full Text] [Related]

  • 5. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
    Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F, CML French Group.
    Blood; 2003 Dec 15; 102(13):4298-305. PubMed ID: 12933584
    [Abstract] [Full Text] [Related]

  • 6. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group.
    N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335
    [Abstract] [Full Text] [Related]

  • 7. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
    Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A.
    J Clin Oncol; 2014 Feb 10; 32(5):415-23. PubMed ID: 24297946
    [Abstract] [Full Text] [Related]

  • 8. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG, Deininger MW.
    Semin Hematol; 2003 Apr 10; 40(2 Suppl 2):26-30. PubMed ID: 12783372
    [Abstract] [Full Text] [Related]

  • 9. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

  • 10. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators.
    N Engl J Med; 2003 Mar 13; 348(11):994-1004. PubMed ID: 12637609
    [Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 12. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP.
    Leukemia; 2003 Dec 15; 17(12):2401-9. PubMed ID: 14523461
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2574-83. PubMed ID: 15493042
    [Abstract] [Full Text] [Related]

  • 14. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
    Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F.
    Blood; 2006 Sep 01; 108(5):1478-84. PubMed ID: 16627756
    [Abstract] [Full Text] [Related]

  • 15. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP, Croom KF, Goa KL.
    BioDrugs; 2004 Sep 01; 18(3):207-10. PubMed ID: 15161340
    [Abstract] [Full Text] [Related]

  • 16. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [Abstract] [Full Text] [Related]

  • 17. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H.
    Cancer; 2007 Sep 15; 110(6):1295-302. PubMed ID: 17623836
    [Abstract] [Full Text] [Related]

  • 18. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2584-92. PubMed ID: 15493041
    [Abstract] [Full Text] [Related]

  • 19. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
    Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.
    Blood; 2008 Mar 01; 111(5):2581-8. PubMed ID: 18172005
    [Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.
    Blood; 2002 May 15; 99(10):3547-53. PubMed ID: 11986206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.